Substance / Medication

Gemifloxacin

Overview

Active Ingredient
gemifloxacin
RxNorm CUI
138099

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

8 trials linked to this intervention

8
Total Trials
0
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Clinical effects of gemifloxacin on the delay of tuberculosis treatment.
Kim Seo Yun, Yim Jae-Joon, Park Jong Sun et al. · J Korean Med Sci · 2013
PMID: 23486643RCTFull text (PMC)
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.
Landersdorfer Cornelia B, Kirkpatrick Carl M J, Kinzig Martina et al. · Antimicrob Agents Chemother · 2009
PMID: 19564368RCTFull text (PMC)
Bioequivalence evaluation of 320 mg gemifloxacin tablets in healthy volunteers.
Al-Mohizea A M, Kadi A A, Al-Bekairi A M et al. · Int J Clin Pharmacol Ther · 2007
PMID: 18077928RCT
High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.
Mahmoudi Laleh, Farshad Shohreh, Seddigh Mehrdad et al. · Medicine (Baltimore) · 2016
PMID: 27759625ObservationalFull text (PMC)
Gemifloxacin mesylate (GFM): dissolution test based on in vivo data.
Paim Clésio Soldateli, Verlindo de Araújo Bibiana, Volpato Nádia Maria et al. · Drug Dev Ind Pharm · 2015
PMID: 24517572Observational
The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.
Kirkcaldy Robert D, Weinstock Hillard S, Moore Page C et al. · Clin Infect Dis · 2014
PMID: 25031289ObservationalFull text (PMC)
Comparative pharmacokinetics and bioavailability of gemifloxacin administered as an intravenous 200 mg formulation or an oral 320 mg tablet.
Kim Mi Jo, Lim Hyeong-Seok, Cho Sang-Heon et al. · Clin Drug Investig · 2014
PMID: 24385283Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Gemifloxacin (substance)
SNOMED CT
407086007
UMLS CUI
C0533545
RxNorm CUI
138099

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
8
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.